Immuron Limited

IMC

AU000000IMC7

Pharmaceuticals

Delayed Australian S.E. Other stock markets 11:55:47 2024-07-15 pm EDT			5-day change	1st Jan Change
0.1 ^AUD	+2.04%		+20.48%	+29.87%

Jul. 15	Immuron Limited Reports Unaudited Sales Results for the Fiscal Fourth Quarter and Full Year Ended June 2024	CI
Jul. 15	Immuron Posts 253% Jump in Travelan Sales in Fiscal Q4; Shares Rise 10%	MT

Immuron Limited Reports Unaudited Sales Results for the Fiscal Fourth Quarter and Full Year Ended June 2024

July 15, 2024 at 08:00 am EDT

Immuron Limited reported unaudited sales results for the fiscal fourth quarter and full year ended June 2024. June 2024 Quarter the company reported global sales of AUD 1.3 million up 253% on prior comparative period and 6% on prior quarter.

For the year, the company reported global sales of AUD 4.9 million up 174% on prior comparative period.

Latest news about Immuron Limited

Immuron Limited Reports Unaudited Sales Results for the Fiscal Fourth Quarter and Full Year Ended June 2024	Jul. 15	CI
Immuron Posts 253% Jump in Travelan Sales in Fiscal Q4; Shares Rise 10%	Jul. 15	MT
Immuron Files for Mixed-Shelf Offering; Plans to Raise $2M Through At-The-Market Equity Sale	Jul. 03	MT
Immuron Requests Meeting With FDA for Potential Colon Infection Therapy	Jul. 02	MT
Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing	Jul. 02	CI
Immuron Files Pre-Investigational New Drug Application with FDA for IMM-529	Jul. 01	MT
Immuron Limited Appoints Jeannette Joughin as Director	Jun. 05	CI
Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	May. 31	CI
Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	May. 02	CI
Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	Apr. 10	CI
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	Apr. 09	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Mar. 07	MT
Sector Update: Health Care	Mar. 07	MT
Top Midday Gainers	Mar. 07	MT
Top Premarket Gainers	Mar. 07	MT
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	Mar. 07	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	Mar. 07	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Immuron Limited Reports Unaudited Net Sales Results for the Year to Date Ended January 2024	Feb. 13	CI
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January	Feb. 12	MT
Immuron Limited Reports Sales Results for First Half 2024	Jan. 16	CI
Immuron Posts Record Travelan Sales in Fiscal H1	Jan. 16	MT
Immuron Limited Clinical Trials Update	Dec. 22	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	Dec. 04	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	23-10-18	CI

Chart Immuron Limited

Duration

Period

More charts

Company Profile

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelerâs diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMURON LIMITED	+29.87%	13.32M
CSL LIMITED	+7.59%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+7.76%	42.63B
BIOGEN INC.	-14.37%	33.5B
UCB	+82.32%	29.77B
BIOMARIN PHARMACEUTICAL INC.	-12.27%	16.14B
INCYTE CORPORATION	+2.33%	14.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.56%	11.55B
ALTEOGEN INC.	+182.74%	10.53B
SWEDISH ORPHAN BIOVITRUM AB	+3.67%	9.2B